Who Buys Ramipril from India — 389 Importers Behind a $89.8M Market

The importers of Ramipril from India can be categorized into several key segments:

1. Pharmaceutical Companies: Entities such as CSP Viatris Santé (France), Wockhardt UK Limited, Crescent Pharma Ltd, Brown and Burk UK Limited, Milpharm Limited, and Apotex Inc. (Canada) fall into this category. These companies procure Ramipril in bulk for formulation, packaging, and distribution under their brand names. Their purchasing behavior is characterized by large-volume orders and long-term contracts to ensure a steady supply chain.

2. Contract Manufacturers: Companies like Milpharm Limited and Brown and Burk UK Limited often operate as contract manufacturers, producing Ramipril for other pharmaceutical brands. They typically place consistent, large-scale orders to meet the demands of their clients, adhering to stringent quality and regulatory standards.

3. Distributors: Entities such as Crescent Pharma Ltd and Apotex Inc. function as distributors, supplying Ramipril to various healthcare providers, pharmacies, and hospitals. Their purchasing patterns involve regular, medium to large-sized orders to maintain adequate inventory levels and meet market demand.

4. Re-exporters: Some companies, including CSP Viatris Santé, may act as re-exporters, importing Ramipril from India and then exporting it to other countries. This segment focuses on leveraging cost advantages and regulatory approvals to supply multiple markets, often placing orders based on the demand in their target export destinations.

Each segment's purchasing behavior is influenced by factors such as market demand, regulatory requirements, and strategic business objectives.

For the top five importing countries, the import regulations for Ramipril are as follows:

It is essential for importers to stay updated with the respective regulatory authorities, as policies and timelines may evolve.

The demand for Ramipril in importing countries is driven by several key factors:

1. Prevalence of Cardiovascular Diseases: Hypertension and heart failure are leading health concerns globally. According to the "Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023" published in JACC in September 2025, the number of prevalent cases of cardiovascular disease reached 626 million globally in 2023, underscoring the vast and growing patient population requiring management for these conditions.

2. Government Healthcare Programs and Universal Health Coverage Expansion: Many countries are enhancing their healthcare infrastructure and expanding coverage, leading to increased access to essential medications like Ramipril. For instance, the inclusion of Ramipril in national formularies and reimbursement schemes facilitates its widespread use.

3. WHO Essential Medicines List Procurement and Tender-Based Purchasing: Ramipril's inclusion in the World Health Organization's Essential Medicines List underscores its importance in treating cardiovascular conditions. This inclusion often leads to bulk procurement through government tenders, ensuring availability in public healthcare systems.

With 389 buyers across 93 countries, the global reach and consistent demand for Ramipril highlight significant market opportunities. The combination of high disease prevalence, supportive healthcare policies, and established procurement mechanisms positions Ramipril as a critical component in cardiovascular disease management worldwide.

The importers of Ramipril from India can be categorized into several key segments:

1. Pharmaceutical Companies: Entities such as CSP Viatris Santé (France), Wockhardt UK Limited, Crescent Pharma Ltd, Brown and Burk UK Limited, Milpharm Limited, and Apotex Inc. (Canada) fall into this category. These companies procure Ramipril in bulk for formulation, packaging, and distribution under their brand names. Their purchasing behavior is characterized by large-volume orders and long-term contracts to ensure a steady supply chain.

2. Contract Manufacturers: Companies like Milpharm Limited and Brown and Burk UK Limited often operate as contract manufacturers, producing Ramipril for other pharmaceutical brands. They typically place consistent, large-scale orders to meet the demands of their clients, adhering to stringent quality and regulatory standards.

3. Distributors: Entities such as Crescent Pharma Ltd and Apotex Inc. function as distributors, supplying Ramipril to various healthcare providers, pharmacies, and hospitals. Their purchasing patterns involve regular, medium to large-sized orders to maintain adequate inventory levels and meet market demand.

4. Re-exporters: Some companies, including CSP Viatris Santé, may act as re-exporters, importing Ramipril from India and then exporting it to other countries. This segment focuses on leveraging cost advantages and regulatory approvals to supply multiple markets, often placing orders based on the demand in their target export destinations.

Each segment's purchasing behavior is influenced by factors such as market demand, regulatory requirements, and strategic business objectives.

For the top five importing countries, the import regulations for Ramipril are as follows:

It is essential for importers to stay updated with the respective regulatory authorities, as policies and timelines may evolve.

The demand for Ramipril in importing countries is driven by several key factors:

1. Prevalence of Cardiovascular Diseases: Hypertension and heart failure are leading health concerns globally. According to the "Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023" published in JACC in September 2025, the number of prevalent cases of cardiovascular disease reached 626 million globally in 2023, underscoring the vast and growing patient population requiring management for these conditions.

2. Government Healthcare Programs and Universal Health Coverage Expansion: Many countries are enhancing their healthcare infrastructure and expanding coverage, leading to increased access to essential medications like Ramipril. For instance, the inclusion of Ramipril in national formularies and reimbursement schemes facilitates its widespread use.

3. WHO Essential Medicines List Procurement and Tender-Based Purchasing: Ramipril's inclusion in the World Health Organization's Essential Medicines List underscores its importance in treating cardiovascular conditions. This inclusion often leads to bulk procurement through government tenders, ensuring availability in public healthcare systems.

With 389 buyers across 93 countries, the global reach and consistent demand for Ramipril highlight significant market opportunities. The combination of high disease prevalence, supportive healthcare policies, and established procurement mechanisms positions Ramipril as a critical component in cardiovascular disease management worldwide.